Drug study on dexamethasone PDF

A Drug Study on
DEXAMETHASONE
In Partial Fulfillment of the
Requirements on NCM 209 – RLE
OB/GYNE NURSING ROTATION
Submitted to:
TRINA A. DOMANAIS RN, MAN
Clinical Instructor
Submitted by:
ELMER S. CORONEL JR. St. N.
BSN-2H Group 4
March 3, 2021

GENERIC NAME: Dexamethasone
BRAND NAME: Dexamethasone
Trade Names: Decadron, Dexasone, Diodex, Hexadrol, and Maxidex.
Other Names: Dexamethasone sodium phosphate, Dexamethasone acetate
CLASSIFICATION
PHARMACOTHERAPEUTIC: Long-acting glucocorticoid
CLINICAL: Corticosteroid
MODE OF ACTION
Suppresses neutrophil migration, decreases production of inflammatory mediators, reverses increased
capillary permeability.
Therapeutic Effect: Decreases inflammation. Suppresses normal immune response.
DOSE AND ROUTE
ANTI-INFLAMMATORY
PO, IV, IM
ADULTS, ELDERLY: 0.75-9 mg/day in divided doses q6-12h.
CHILDREN: 0.08-0.3 mg/kg/day in divided doses q6-12h
CEREBRAL EDEMA
IV
ADULTS, ELDERLY: Initially, 10 mg, then 4 mg (IV or IM) q6h.
PO, IV, IM

CHILDREN: Loading dose of 1-2 mg/kg, then 1-1.5 mg/kg/day in divided doses q4-6h
NAUSEA/VOMITING IN CHEMOTHERAPY PTS
IV
ADULTS, ELDERLY: 10-20 mg 15-30 min before treatment
CHILDREN: 10 mg/m2/dose on days of chemotherapy
PHYSIOLOGIC REPLACEMENT
PO, IV, IM
ADULTS, ELDERLY, CHILDREN: 0.03-0.15 mg/kg/day in divided doses q6-12h
USUAL OPHTHALMIC DOSAGE, OCULAR INFLAMMATORY CONDITIONS
Suspension: ADULTS, ELDERLY, CHILDREN: Initially, 2 drops q1h while awake and q2h at
night for 1 day, then reduce to 3-4 times a day
Dosage in Renal/Hepatic Impairment
No dose adjustment
INDICATION
Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity
reactions, perennial or seasonal allergic rhinitis, and serum sickness.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and
severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of
choice; may be used in conjunction with synthetic miner-alocorticoid analogs where
applicable;in infancy mineralocorticoid supplementation is of particular
importance), congenital adrenal hyperplasia, hypercal-cemia associated with cancer, and
nonsuppurative thyroiditis.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders